Nephros Reports Departure of Director

Reports Departure of Director

YORK, NY - May 1, 2007 - Nephros, Inc.

announced that, on April 30, 2007, Donald G. Drapkin submitted his

resignation from the Company's Board of Directors (the "Board") effective

immediately to pursue other business interests. Mr. Drapkin had no disagreements

with the Company on any matters related to the Company's operations, policies

J. Fox, Executive Chairman of the Board stated, "On behalf of the entire Board

of Nephros, I want to thank Donald for his dedicated service and many valued

contributions to the Company. We all wish Donald good luck and much success

his new business activities."

Drapkin's resignation, the Company's Board now has eight members plus one

vacancy. The Company expects that prior to its upcoming annual meeting of

stockholders to be held on May 22, 2007, the Company's remaining directors, with

the guidance of the Company's Nominating and Corporate Governance Committee,

will eliminate such vacancy either by electing a new director or by reducing

number of directors that constitute the whole Board.

Inc., headquartered in New York, is a medical device company developing and

marketing products designed to improve the quality of life for the End-Stage

Renal Disease (ESRD) patient, while addressing the critical financial and

clinical needs of the care provider. ESRD is a disease state characterized

the irreversible loss of kidney function. Nephros believes that its products,

particularly its Mid-Dilution Hemodiafiltration therapy, are designed to

a range of harmful substances more effectively, and more cost-effectively,

existing ESRD treatment methods; particularly with respect to substances

collectively as "middle molecules," due to their molecular weight, that have

been found to contribute to such conditions as dialysis-related amyloidosis,

carpal tunnel syndrome, degenerative bone disease and, ultimately, mortality

the ESRD patient. Nephros products are currently being used in over fifty

clinics in Europe, and are distributed in Italy, France and Belgium.

also markets a line of water filtration products, the Dual Stage Ultrafilter

(DSU). The Company's patented dual stage cold sterilization Ultrafilter has

capability to filter out bacteria and, due to its exceptional filtration

filter out many viruses and parasites. The DSU proprietary design provides

dual-stage filtration reducing the risk of filtration failure. With initial

focus on health care, the DSU is in a pilot-use program at a major medical

center and has been selected for further development by the US Marine Corps.

Company considers the DSU a significant breakthrough in providing affordable

reliable water filtration. The DSU is based on Nephros' proprietary

technology originally designed for medical use in its H2H machine, and is

complimentary product line to the Company's main focus, the ESRD therapy

information on Nephros please visit the Company's website, www.nephros.com.

release contains certain "forward-looking statements" within the meaning

Private Securities Litigation Reform Act of 1995, as amended. Such statements

may include statements regarding the efficacy and intended use of Nephros'

technologies, the timelines for bringing such products to market and the

availability of funding sources for continued development of such products

other statements that are not historical facts, including statements which

be preceded by the words "intends," "may," "will," "plans," "expects,"

"anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes,"

"potential" or similar words. For such statements, Nephros claims the protection

of the Private Securities Litigation Reform Act of 1995.

statements are not guarantees of future performance are based on certain

assumptions and are subject to various known and unknown risks and

uncertainties, many of which are beyond the control of Nephros. Actual results

may differ materially from the expectations contained in the forward-looking

statements. Factors that may cause such differences include the risks that:

products that appeared promising to Nephros in research or clinical trials

not demonstrate anticipated efficacy, safety or cost savings in subsequent

pre-clinical or clinical trials; (ii) Nephros may not obtain appropriate

necessary governmental approvals to achieve its business plan or effectively

market its products; (iii) Nephros may not to satisfy its debt obligations

they become due and payable and meet its anticipated cash needs and may not

successful in obtaining additional funding in order to continue operations

fund its clinical trials; and (iv) Nephros may be unable to show progress

consistent with its plan of compliance to meet the American Stock Exchange's

continued listing standards or may be otherwise unable to timely regain

compliance with the AMEX listing standards. More detailed information about

Nephros and the risk factors that may affect the realization of forward-looking

statements is set forth in Nephros' filings with the Securities and Exchange

Commission, including Nephros' Annual Report on Form 10-KSB filed with the

for the fiscal year ended December 31, 2006. Investors and security holders

urged to read this document free of charge on the SEC's web site at www.sec.gov.

does not undertake to publicly update or revise its forward-looking statements

as a result of new information, future events or otherwise.